Available at: PubMed Cerovecki T, Bojanic I, Brcic L, et al
Specifically approved for weight management in adults with a BMI of 30 or higher, or 27 and above with one weight-related health condition, Wegovy has demonstrated an average weight loss of 15% over 68 weeks in clinical trials
Los ensayos clnicos no identificaron cambios significativos en hemoglobina o hematocrito, y la anemia no figura como efecto adverso en la informacin de prescripcin aprobada por la FDA
Different GLP-1 receptor agonists have different stability profiles
But for active adults using these medications, resistance training should be treated as a non-negotiable part of the overall plan to help preserve muscle and maintain healthy mechanical loading on the skeleton
Barboi Clinical Autonomic Research.2023